• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ultragenyx Pharmaceu (NQ: RARE )

    44.75 -2.89 (-6.07%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Ultragenyx Pharmaceu

    < Previous 1 2 3 4 5 Next >
    Evaluating Ultragenyx Pharmaceutical: Insights From 7 Financial Analysts
    Via Benzinga
    A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast
    Via Benzinga
    Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
    Via Benzinga
    Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
    Via Benzinga
    Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
    Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    3 Genomics Stocks That May Transform Personalized Medicine
    These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. 
    Via InvestorPlace
    Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
    Via Benzinga
    Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
    Via Benzinga
    Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
    Via Benzinga
    Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
    Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
    Via Benzinga
    Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
    Biogen previously decided against opting into Ionis' Angelman program. 
    Via Investor's Business Daily
    7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
    With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities. 
    Via InvestorPlace
    Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
    Via Benzinga
    Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
    Via Benzinga
    Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
    The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against... 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
    RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
    U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
    Via Benzinga
    Recap: Ultragenyx Pharmaceutical Q4 Earnings
    Via Benzinga
    The Latest Analyst Ratings For Ultragenyx Pharmaceutical
    Via Benzinga
    Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic... 
    Via Benzinga
    Crude Oil Down 1%; Charles Schwab Sales Top Estimates
    U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P... 
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Earnings Scheduled For February 15, 2024
    Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
    Via Benzinga
    Preview: Ultragenyx Pharmaceutical's Earnings
    Via Benzinga
    4 Analysts Have This To Say About Ultragenyx Pharmaceutical
    Via Benzinga
    Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
    New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. 
    Via Benzinga
    Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
    On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. 
    Via Investor's Business Daily
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.